Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BERLEX LABS HAS NDAs FOR TWO IMAGING AGENTS PENDING AT FDA

Executive Summary

BERLEX LABS HAS NDAs FOR TWO IMAGING AGENTS PENDING AT FDA, the company told "The Pink Sheet." Applications for the myelographic agent iotrolan and gadolinium DPTA, a contrast agent for use in the magnetic imaging of head and neck lesions, were filed with the agency in February and August, respectively. Berlex explained that the two filings are indicative of the firm's increased emphasis on diagnostic imaging. Both compounds were initially developed by Berlex' West German parent, Schering AG. According to the company, gadolinium DPTA is the first contrast agent for magnetic resonance imaging, and the U.S. is the first country in which regulatory approval is being sought. In addition, Berlex has two anti-arrhythmic drugs in clinical study -- CK 1752, a compound developed in-house which should be in Phase II by year end, and dipraphenone, a product licensed from the German firm Helopharm and currently in Phase II. Also in Phase II is the prostacycline compound, iloprost, for use in cardiopulmonary bypass surgery.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel